Sirius XM Holdings Inc. (SIRI) closed at $3.55 and is still under its supposed buyout price. Macquarie has raised the rating to Outperform from Neutral and believes that Sirius is worth $4 per share, versus a prior $3.75 price target. The firm believes that the minority shareholders are now in a better bargaining position, and it sees growth ahead in the next three-year period.
TRADE QUALITY 100%, Excellent
High trade quality is a combination of good profit, profit/loss ratio and target potential.
TARGET 1 Price: 4.4 Profit: 24.3% , for a typical rally.
Stop Limit/Trailing Stop Limit: 3.3 Loss: 6.8%
Profit/Loss Ratio: 3.6 : 1 - Good
TARGET 1 POTENTIAL Excellent, there are 1 resistance areas on the way to Target 1.
Stocks may quickly rise to Targets when there are not many resistance areas blocking the way.
TARGET 1 RESISTANCE +16.9% at 4.14 ± 0.22, type Single, strength 5
+24.3% at 4.4 is Target 1
TARGET 2 Price: 4.72 Profit: 33.3% , Profit/Loss Ratio: 4.9 : 1 - Excellent for an extreme rally.
Finally, Cramer said he actually likes Groupon (GRPN) at current levels, despite the company reporting a worse-than-expected earnings result.
One biotechnology player that could be preparing to put a hurting on the shorts is Achillion Pharmaceuticals (ACHN_), which discovers, develops and commercializes anti-infective drug therapies in the U.S. and internationally. This stock is off to a decent start in 2014, with shares up around 11%.
The current short interest as a percentage of the float for Achillion International is extremely high at 29.7%. That means that out of the 56.17 million shares in the tradable float, 16.7 million shares are sold short by the bears. This is a monster short interest on a stock with a relatively low float. If buyers step up to the plate on ACHN soon, then we could easily see a huge short-squeeze.
If you take a glance at the chart for Achillion Pharmaceuticals, you'll notice that this stock has been uptrending for the last month, with shares moving higher from its low of $2.98 to its recent high of $3.87 a share. During that uptrend, shares of ACHN have been making mostly higher lows and higher highs, which is bullish technical price action. This move is quickly pushing shares of ACHN within range of triggering a big breakout trade that could send the shorts running for cover.
Traders should now look for long-biased trades in ACHN if it manages to break out above some near-term overhead resistance levels at $3.87 to $4 a share with strong volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 2.11 million shares. If that breakout materializes soon, then ACHN will set up ACHN for a possible squeeze higher back towards its next major overhead resistance level at $4.36 a share. Any high-volume move above that level will then give ACHN a chance to re-fill some of its previous gap-down-day zone from last September that started above $7 a share
Traders can look to buy ACHN off weakness to anticipate that breakout and simply use a stop that sits right below some near-term support at $3.35 a share.
In trading on Friday, shares of Groupon Inc. (NASD: GRPN) entered into oversold territory, hitting an RSI reading of 27.5, after changing hands as low as $8.42 per share. By comparison, the current RSI reading of the S&P 500 ETF (SPY) is 61.1. A bullish investor could look at GRPN’s 27.5 RSI reading today as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side
Target: 5.69 - Excellent
Target: 5.30 - Good
Zynga Cl A: (NASD: ZNGA)
(U.S: NASD) As of Feb 14, 2014 01:11 PM ET
Zacks Rank : 1-Strong Buy [?]
Sentiment: Strong Buy
Coronado Biosciences Inc: (NASD: CNDO)
(U.S: NASD) As of Feb 13, 2014 10:28 AM ET
Zacks Rank : 1-Strong Buy
Sentiment: Strong Buy
Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion, will present a corporate overview at two upcoming investor conferences:
-- Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 8:55 a.m. ET at the Waldorf Astoria Hotel in New York, NY; and
-- Cowen and Company 34 Annual Health Care Conference on Monday, March 3, 2014 at 1:30 p.m. ET at The Boston Marriott Copley Place in Boston, MA.